The Warburg effect as a therapeutic target for bladder cancers and intratumoral heterogeneity in associated molecular targets

• Published in: Cancer science Vol. 112; no. 9; pp. 3822 - 3834
• Main Authors: Burns, Julie E., Hurst, Carolyn D., Knowles, Margaret A., Phillips, Roger M., Allison, Simon J.
• Format: Journal Article
• Language: English
• Published: Tokyo John Wiley & Sons, Inc 01.09.2021; John Wiley and Sons Inc
• Subjects: Analysis; Apoptosis; Bladder cancer; Cancer; Cancer therapies; Cell death; Chemotherapy; Dehydrogenases; Enzymes; epithelial‐mesenchymal transition; Experiments; FDA approval; Gene expression; Genomes; Glucose; Glucose metabolism; Glycolysis; Growth factors; Health aspects; intratumoral heterogeneity; Invasiveness; Kinases; L-Lactate dehydrogenase; lactate dehydrogenase A; Lactic acid; Mesenchyme; Metabolism; Mutation; non–muscle‐invasive and muscle‐invasive bladder cancers; Original; Patients; Phosphorylation; Proteins; Pyruvic acid; Radiation therapy; RNA-mediated interference; Therapeutic applications; Therapeutic targets; Tumor cell lines; Urothelial cancer; Warburg effect

Bladder cancer is the 10th most common cancer worldwide. For muscle‐invasive bladder cancer (MIBC), treatment includes radical cystectomy, radiotherapy, and chemotherapy; however, the outcome is generally poor. For non–muscle‐invasive bladder cancer (NMIBC), tumor recurrence is common. There is an u...